GT Medical Technologies

The firm makes GammaTile, a bioresorbable collagen tile embedded with radiation seeds that neurosurgeons place in the tumor cavity at the time of brain-tumor removal surgery. It is the first and only tile-based radiation therapy cleared by the FDA. The tile begins irradiating residual tumor cells immediately and dissolves over several weeks, eliminating the need for removal and avoiding the standard multi-week delay between surgery and external-beam radiation.

GammaTile is FDA-cleared for three operable brain-tumor categories: newly diagnosed glioblastoma, recurrent glioblastoma, brain metastases (both newly diagnosed and recurrent), and recurrent meningiomas. Collectively these represent the highest-volume intracranial tumors requiring post-resection radiation.

Standard external-beam radiation typically begins two to eight weeks after surgery because the surgical site must heal before conventional radiation can be tolerated. GammaTile is placed directly in the resection cavity during surgery and begins delivering radiation from day one — roughly 90 percent of the total dose is delivered within the first 30 days. The collagen tile physically separates the radiation sources from healthy brain tissue, reducing collateral dose. There is no daily hospital visit and no fractionated schedule.

The firm’s website does not disclose a parent company, corporate structure, or named investors. No public funding rounds, executive team, or board of directors are listed in the firm’s online presence. The available information does not confirm venture backing or affiliation with a larger strategic — only that the entity operates commercially out of Tempe, Arizona under the GammaTile brand.

The firm maintains a 'Find a GammaTile Center' locator on its website mapping clinical sites across the United States. The treatment requires a neurosurgeon and a radiation-oncology team that have integrated GammaTile into their surgical workflow; patients identify a participating center through the locator and then confirm candidacy with the care team.